Schrodinger Inc. (SDGR)
NASDAQ: SDGRHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
SDGR stock chart
Technical analysisKey statistics
All statistics- Market cap
- $1.72B
- EPS (TTM)
- -$0.79
- Dividend yield
- None
- 52-week range
- 10.95 – 34.00
- Day range
- 22.75 – 26.30
- Volume / Avg
- 1.88M / 2.08M
- Beta
- —
- Shares outstanding
- 65.91M
52-week range
SDGR stock today
On Nov 20, SDGR ended the session at $22.93, shedding $3.41 (12.95%), versus the S&P 500's 3.70% decline. At this level, SDGR sits in the middle of its 52-week range of $10.95 to $34.00: 32.6% below the high, set on Nov 11, 2026 and 109.5% above the low. SDGR is up 28.2% year to date, outperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has gained 39.2%.
Schrodinger has posted a net loss over the last twelve months (EPS of -$0.79), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About Schrodinger
Company profileSchrödinger, Inc., together with its subsidiaries, develops physics-based computational platform that enables discovery of novel molecules for drug development and materials applications in the United States, the Asia-Pacific, Europe, Middle East, Africa, and internationally. The company operates in two segments, Software and Drug Discovery. The Software segment sells its software to transform molecular discovery for life sciences and materials science industries.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Dr. Ramy Farid Ph.D.
- Headquarters
- New York, NY
- Employees
- 850
- IPO year
- 2020
- Website
- schrodinger.com
Financial highlights
Full financialsIn fiscal 2025, Schrodinger generated $255.9 million in revenue, up 23.3% from fiscal 2024. Schrodinger reported a net loss of $103.3 million, compared with a loss of $187.1 million a year earlier. Gross margin was 55.7% (down from 63.6%) and operating margin -65.2%.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | $255.87M | $207.54M | $216.67M | $180.96M | $137.93M |
| Growth | +23.29% | -4.21% | +19.73% | +31.19% | +27.60% |
| Net income | $-103.27M | $-187.12M | $40.72M | $-149.19M | $-100.39M |
| EPS (diluted) | $-1.41 | $-2.57 | $0.54 | $-2.10 | $-1.42 |
Analyst forecast
ForecastConsensus (7 analysts)
buy
Avg. price target
$33.57+46.40%
- Strong buy 0
- Buy 5
- Hold 2
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 4, 2026
- EPS actual vs est.
- $-0.50 vs $-0.66
- Surprise
- +24.24%
SDGR news
All SDGR news- Schrödinger Consensus Price Target Increased by 24.57% to $31.77Nasdaq
- Schrödinger Reports Third Quarter 2026 Financial ResultsBusiness Wire
- Earnings Preview: Schrodinger, Inc. (SDGR) Q3 Earnings Expected to DeclineNasdaqSDGR, TEM
- SDGR Crosses Above Average Analyst TargetNasdaq
- Schrödinger Consensus Price Target Increased by 16.67% to $25.50Nasdaq
- Schrödinger to Announce Third Quarter 2026 Financial Results on November 4Business Wire
- Notable Thursday Option Activity: BA, HOOD, SDGRNasdaqBA, HOOD, SDGR
- Biotech Stocks At 52-Week Highs - MNOV +8%, RVTY +8%, TXG +6%, TLX +9%, SDGR +12%NasdaqMNOV, RVTY, SDGR, TLX
Schrodinger peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| KRSAKorsana Biosciences Inc. | 37.56 | +5.95% | $1.71B | vs SDGR |
| TRAXFirst Tracks Biotherapeutics Inc. | 41.64 | -6.34% | $1.75B | vs SDGR |
| STOKStoke Therapeutics Inc. | 26.81 | -0.45% | $1.75B | vs SDGR |
| ETONEton Pharmaceuticals Inc. | 60.85 | -0.83% | $1.76B | vs SDGR |
| RAREUltragenyx Pharmaceutical Inc. | 16.48 | -4.30% | $1.68B | vs SDGR |
| BRVEBraveheart Bio Inc. | 20.39 | +5.81% | $1.67B | vs SDGR |
| AGIOAgios Pharmaceuticals Inc. | 27.60 | -4.03% | $1.65B | vs SDGR |
| ZYMEZymeworks Inc. | 26.14 | -2.68% | $1.81B | vs SDGR |
Indexes, lists and sector
Schrodinger stock FAQ
What is Schrodinger's stock price today?
SDGR last traded at $22.93 as of Nov 20, 4:00 PM EST, down 12.95% on the day. Prices are delayed at least 15 minutes.
Who is Schrodinger's CEO?
Dr. Ramy Farid Ph.D. is the chief executive officer of Schrodinger Inc., which has about 850 employees.
What is the SDGR 52-week high?
The 52-week high for SDGR is $34.00 and the 52-week low is $10.95. The stock is currently 32.6% below its high.